PAZOPANIB HYDROCHLORIDE

N/A

Manufactured by Novartis Pharmaceuticals Corporation

49,320 FDA adverse event reports analyzed

Last updated: 2026-04-14

About PAZOPANIB HYDROCHLORIDE

PAZOPANIB HYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Novartis Pharmaceuticals Corporation. The most commonly reported adverse reactions for PAZOPANIB HYDROCHLORIDE include DEATH, DIARRHOEA, FATIGUE, NAUSEA, MALIGNANT NEOPLASM PROGRESSION. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for PAZOPANIB HYDROCHLORIDE.

Top Adverse Reactions

DEATH4,570 reports
DIARRHOEA3,591 reports
FATIGUE2,483 reports
NAUSEA2,417 reports
MALIGNANT NEOPLASM PROGRESSION1,648 reports
DRUG INEFFECTIVE1,461 reports
DECREASED APPETITE1,436 reports
VOMITING1,402 reports
HYPERTENSION1,250 reports
DISEASE PROGRESSION997 reports
ASTHENIA929 reports
MALAISE900 reports
WEIGHT DECREASED880 reports
DYSPNOEA839 reports
HAIR COLOUR CHANGES825 reports
BLOOD PRESSURE INCREASED782 reports
PRODUCT USE IN UNAPPROVED INDICATION761 reports
HEADACHE714 reports
PAIN670 reports
ABDOMINAL PAIN514 reports
DYSGEUSIA504 reports
PYREXIA504 reports
RASH497 reports
ABDOMINAL PAIN UPPER490 reports
OFF LABEL USE439 reports
ABDOMINAL DISCOMFORT418 reports
PAIN IN EXTREMITY415 reports
DIZZINESS407 reports
DEHYDRATION401 reports
HEPATIC ENZYME INCREASED389 reports
CONSTIPATION388 reports
COUGH376 reports
ANAEMIA375 reports
ALANINE AMINOTRANSFERASE INCREASED365 reports
METASTASES TO LUNG363 reports
PLATELET COUNT DECREASED341 reports
PNEUMONIA336 reports
BACK PAIN335 reports
STOMATITIS323 reports
ARTHRALGIA321 reports
GENERAL PHYSICAL HEALTH DETERIORATION314 reports
PALMAR PLANTAR ERYTHRODYSAESTHESIA SYNDROME312 reports
ALOPECIA302 reports
ASPARTATE AMINOTRANSFERASE INCREASED289 reports
THROMBOCYTOPENIA287 reports
HEPATIC FUNCTION ABNORMAL285 reports
RENAL CELL CARCINOMA276 reports
PLEURAL EFFUSION272 reports
NEOPLASM MALIGNANT263 reports
BLOOD BILIRUBIN INCREASED261 reports
HYPOTHYROIDISM248 reports
NEOPLASM PROGRESSION238 reports
CHEST PAIN233 reports
AGEUSIA226 reports
RENAL IMPAIRMENT225 reports
MUSCLE SPASMS224 reports
HOSPITALISATION222 reports
DRUG INTOLERANCE216 reports
EPISTAXIS216 reports
RENAL CANCER213 reports
LIVER DISORDER211 reports
ADVERSE DRUG REACTION208 reports
HEPATOTOXICITY207 reports
GAIT DISTURBANCE206 reports
DRUG INTERACTION202 reports
PROTEINURIA200 reports
PRURITUS200 reports
DYSPEPSIA198 reports
JAUNDICE196 reports
FEELING ABNORMAL195 reports
BLOOD CREATININE INCREASED192 reports
FALL190 reports
MYALGIA189 reports
SKIN DISCOLOURATION187 reports
CONFUSIONAL STATE184 reports
CARDIAC FAILURE183 reports
CEREBROVASCULAR ACCIDENT183 reports
DRUG DOSE OMISSION183 reports
PNEUMOTHORAX182 reports
OEDEMA PERIPHERAL180 reports
RENAL FAILURE180 reports
HOSPICE CARE177 reports
LIVER FUNCTION TEST ABNORMAL175 reports
METASTATIC RENAL CELL CARCINOMA175 reports
ACUTE KIDNEY INJURY173 reports
METASTASES TO LIVER173 reports
METASTASES TO CENTRAL NERVOUS SYSTEM168 reports
METASTASES TO BONE167 reports
PRODUCT USE ISSUE165 reports
NEUTROPENIA163 reports
MYOCARDIAL INFARCTION161 reports
INSOMNIA160 reports
ERYTHEMA158 reports
ABDOMINAL DISTENSION156 reports
BLISTER155 reports
PERIPHERAL SWELLING154 reports
PULMONARY EMBOLISM154 reports
URINARY TRACT INFECTION152 reports
ASCITES150 reports
DYSPHONIA150 reports

Report Outcomes

Out of 26,719 classified reports for PAZOPANIB HYDROCHLORIDE:

Serious 66.7%Non-Serious 33.3%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Male13,972 (58.4%)
Female9,813 (41.0%)
Unknown138 (0.6%)

Reports by Age

Age 63498 reports
Age 70476 reports
Age 62472 reports
Age 65469 reports
Age 64448 reports
Age 61438 reports
Age 68434 reports
Age 60431 reports
Age 67422 reports
Age 69403 reports
Age 66398 reports
Age 71395 reports
Age 72378 reports
Age 59375 reports
Age 73363 reports
Age 58351 reports
Age 75350 reports
Age 76349 reports
Age 74345 reports
Age 56333 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with PAZOPANIB HYDROCHLORIDE?

This profile reflects 49,320 FDA FAERS reports that mention PAZOPANIB HYDROCHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for PAZOPANIB HYDROCHLORIDE?

Frequently reported terms in FAERS include DEATH, DIARRHOEA, FATIGUE, NAUSEA, MALIGNANT NEOPLASM PROGRESSION, DRUG INEFFECTIVE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures PAZOPANIB HYDROCHLORIDE?

Labeling and FAERS entries often list Novartis Pharmaceuticals Corporation in connection with PAZOPANIB HYDROCHLORIDE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.